Rivaroxaban presents a better pharmacokinetic profile than dabigatran in an obese non-diabetic stroke patient

J Neurol Sci. 2014 Nov 15;346(1-2):366-7. doi: 10.1016/j.jns.2014.09.008. Epub 2014 Sep 16.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antithrombins / pharmacokinetics*
  • Antithrombins / therapeutic use
  • Benzimidazoles / pharmacokinetics*
  • Benzimidazoles / therapeutic use
  • Dabigatran
  • Humans
  • Male
  • Morpholines / pharmacokinetics*
  • Morpholines / therapeutic use
  • Rivaroxaban
  • Stroke / prevention & control*
  • Thiophenes / pharmacokinetics*
  • Thiophenes / therapeutic use
  • beta-Alanine / analogs & derivatives*
  • beta-Alanine / pharmacokinetics
  • beta-Alanine / therapeutic use

Substances

  • Antithrombins
  • Benzimidazoles
  • Morpholines
  • Thiophenes
  • beta-Alanine
  • Rivaroxaban
  • Dabigatran